1. Medtech Insight
  2. >>Business

Invitae Claws At $50m, Selling Reproductive Health Assets

 
• By Barnaby Pickering

Natera has pounced on the opportunity to purchase Invitae’s reproductive health assets at a bargain price, simultaneously quashing any potential ongoing royalty payments between the two.

• Source: Shutterstock

After posting consistently poor financial results, genetic-test developerInvitae has implemented its most drastic cost-saving measure to date, selling off its reproductive health business to Natera.

Natera has had legal disputes with Invitae before, but will get Invitae’s reproductive health business for the bargain price of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Even ‘Small’ Leaks After Left Atrial Appendage Occlusion Raises Stroke Risk, Study Finds

 
• By Brian Bossetta

A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By Elizabeth Orr

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

German Hospital Reform Risks Spiraling Out Of Control

 
• By Ashley Yeo

Amendments to Germany’s – barely in force – health reform law will be decided after the summer break. The new DRGs payments plan and service groups will be reviewed, but critics fear for the law’s future.